Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 499-512 , August 2009

Therapeutic potential for GIP receptor agonists and antagonists

  • Nigel Irwin, PhD (Research Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 2870 324313; Fax: +44 2870 324965.
    • ,
  • Peter R. Flatt (Professor)

References 

  1. Unger RH, Eisentraut AM. Entero-insular axis. Archives of Internal Medicine. 1969;123:261–266
  2. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. The Journal of Clinical Endocrinology and Metabolism. 1964;24:1076–1082
  3. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. The Journal of Clinical Investigation. 1967;46:1954–1962
  4. Creutzfeldt M. Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology. 1974;67:748–750
  5. Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539
  6. Takeda J, Seino Y, Tanaka K-I, et al. Sequence of an intestinal cDNA encoding gastric inhibitory polypeptide precursor. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:7005–7008
  7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  8. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52
  9. Brown JC, Pederson RA, Jorpes E, et al. Preparation of a highly active enterogastrone. Canadian Journal of Physiology and Pharmacology. 1969;47:113–114
  10. Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its physiological release and insulinotropic action in the dog. Diabetes. 1975;24:1050–1056
  11. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology. 1976;99:780–785
  12. Andersen DK, Elahi D, Brown JC, et al. Oral glucose augmentation of insulin secretion: interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. The Journal of Clinical Investigation. 1978;62:152–161
  13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157
  14. Tsukiyama K, Yamada Y, Yamada C, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Molecular Endocrinology. 2006;20:1644–1651
  15. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Molecular and Cellular Endocrinology. 2001;177:35–41
  16. Nyberg J, Anderson MF, Meister B, et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. The Journal of Neuroscience. 2005;25:1816–1825
  17. Ding KH, Zhong Q, Xie D, et al. Effects of glucose-dependent insulinotropic polypeptide on behavior. Peptides. 2006;27:2750–2755
  18. Simpson AK, Ward PS, Wong KY, et al. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia. 2007;50:2181–2189
  19. Mazzocchi G, Rebuffat P, Meneghelli V, et al. Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway. Peptides. 1999;20:589–594
  20. Gault VA, Hölscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Journal of Neurophysiology. 2008;99:1590–1595
  21. Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Molecular Endocrinology. 2001;15:1559–1570
  22. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells. The Journal of Endocrinology. 2002;174:233–245
  23. Ehses JA, Pellech SL, Pederson RA, et al. Glucose-dependent insulinotropic polypeptide (GIP) activates the Raf-Mek 1/2-ERK 1/2 module via a cyclic AMP/PKA/Rap1-mediated pathway. The Journal of Biological Chemistry. 2002;277:37088–37097
  24. Wang Y, Montrose-Rafizadeh C, Adams L, et al. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Molecular and Cellular Endocrinology. 1996;116:81–87
  25. Marenah L, McCluskey JT, Abdel-Wahab YH, et al. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biological Chemistry. 2006;387:941–947
  26. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential. Neuropeptides. 2003;37:253–263
  27. Irwin N, Flatt PR, Gault VA. GIP-based therapeutics for diabetes and obesity. Current Opinion in Chemical Biology. 2007;2:61–68
  28. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Hormone and Metabolic Research. 2004;36:830–836
  29. Hargrove DM, Nardone NA, Persson LM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995;44:1231–1237
  30. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613
  31. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation. 1993;91:301–307
  32. Deacon CF, Nauck MA, Meier JJ, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3575–3581
  33. Kjems LL, Holst JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380–386
  34. Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. The Journal of Clinical Investigation. 1984;74:1318–1328
  35. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 2004;53(S3):S220–S224
  36. Kindmark H, Pigon J, Efendic S. Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2015–2019
  37. Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes. 2004;53:2359–2365
  38. Meier JJ, Gallwitz B, Askenas M, et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia. 2005;48:1872–1881
  39. Meier JJ, Nauck MA, Siepmann N, et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism. 2003;52:1579–1585
  40. Højberg PV, Visbøll T, Bache M, et al. Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type 2 diabetes. Diabetologia. 2007;50(Suppl. 1):S111
  41. Aaboe K, Knop FK, Visbøll T, et al. Acute administration of a sulfonylurea compound restores the insulinotropic effect of glucose-dependent polypeptide in patients with type 2 diabetes. Diabetologia. 2007;50(Suppl. 1):S248
  42. Piteau S, Olver A, Kim SJ, et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochemical and Biophysical Research. 2007;362:1007–1012
  43. Younan SM, Rashed LA. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors. General Physiology and Biophysics. 2007;26:181–193
  44. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011
  45. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histadine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry. 1993;214:829–835
  46. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596
  47. Deacon CF, Plamboeck A, Rosenkilde MM, et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology. Endocrinology and Metabolism. 2006;291:E468–E475
  48. Deacon CF, Danielsen P, Klarskov L, et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes. 2001;50:1588–1597
  49. Deacon CF, Wamberg S, Bie P, et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. The Journal of Endocrinology. 2002;172:355–362
  50. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:6874–6879
  51. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clinical Science (London). 2005;108:277–292
  52. Green BD, Flatt PR, Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. Expert Opinion on Emerging Drugs. 2006;11:525–539
  53. O'Harte FP, Mooney MH, Flatt PR. NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes. 1999;48:758–765
  54. O'Harte FP, Mooney MH, Kelly CM, et al. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. The Journal of Endocrinology. 2000;165:639–648
  55. Gault VA, Flatt PR, Bailey CJ, et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochemical Journal. 2002;367:913–920
  56. O'Harte FP, Gault VA, Parker JC, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002;45:1281–1291
  57. Gault VA, Flatt PR, Harriott P, et al. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. The Journal of Endocrinology. 2003;176:133–141
  58. Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002;51:652–661
  59. Meier JJ, Nauck MA. GIP as a potential therapeutic agent?. Hormone and Metabolic Research. 2004;36:859–866
  60. Ribel U, Larsen MO, Rolin B, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. European Journal of Pharmacology. 2002;451:217–225
  61. Irwin N, O'Harte FP, Gault VA, et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. Journal of Medicinal Chemistry. 2006;49:1047–1054
  62. Irwin N, Gault VA, Green BD, et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biological Chemistry. 2005;386:679–687
  63. Irwin N, Green BD, Gault VA, et al. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. Journal of Medicinal Chemistry. 2005;48:1244–1250
  64. Hinke SA, Manhart S, Pamir N, et al. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochimica et Biophysica Acta. 2001;1547:143–155
  65. Irwin N, Green BD, Mooney MH, et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. The Journal of Pharmacology and Experimental Therapeutics. 2005;314:1187–1194
  66. Irwin N, Clarke GC, Green BD, et al. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochemical Pharmacology. 2006;72:719–728
  67. Irwin N, Green BD, Gault VA, et al. Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice. Peptides. 2006;27:893–900
  68. Irwin N, Green BD, Gault VA, et al. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Experimental Gerontology. 2006;41:151–156
  69. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews. 2002;54:459–476
  70. Gault VA, Kerr BD, Irwin N, et al. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochemical Pharmacology. 2008;75:2325–2333
  71. Salhanick AI, Clairmont KB, Buckholz TM, et al. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorganic & Medicinal Chemistry Letters. 2005;15:4114–4117
  72. Chen D, Liao J, Li N, et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:943–948
  73. Knudsen LB, Kiel D, Teng M, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America. 2007 Jan 16;104(3):937–942
  74. Gedulin B, Hargrave D, Smith P et al. Insulinotropic actions of a long-acting GIP analog AC163794 in vivo. In: Program and abstracts of the 67th Scientific Sessions of the American Diabetes Association. 2007. p. 1485.
  75. Lindsay JR, Au STB, Kelly CMN, et al. A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes. 2002;S5:1394
  76. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sciences. 2000;66:91–103
  77. Ross SA, Dupre J. Effects of ingestion of triglycerides or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes. 1978;27:327–333
  78. Falko JM, Crockett SE, Cataland S, et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. The Journal of Clinical Endocrinology and Metabolism. 1975;41:260–265
  79. Salera M, Giacomoni P, Pironi L, et al. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. The Journal of Clinical Endocrinology and Metabolism. 1982;55:329–336
  80. Marks V. In:  James WPT,  Parker SW editor. Current approaches: obesity. Southampton: Duphar Medical Relations; 1988;p. 13–19
  81. Flatt PR, Bailey CJ, Kwasowski P, et al. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes. 1983;32:433–435
  82. Bailey CJ, Flatt PR, Kwasowski P, et al. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinologica. 1986;112:224–229
  83. O'Harte FPM, Hunter K, Gault VA, et al. Antagonistic effects of two novel GIP analogues, (Hyp3)GIP and (Hyp3)GIPLys16PAL on the biological actions of GIP and longer term effects in diabetic ob/ob mice. American Journal of Physiology. 2007;292:E1674–E1682
  84. Gault VA, O'Harte FP, Harriott P, et al. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochemical and Biophysical Research. 2002;290:1420–1426
  85. Gault VA, O'Harte FP, Harriott P, et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46:222–230
  86. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:14843–14847
  87. Irwin N, Gault VA, Green BD, et al. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological Chemistry. 2004;385:845–852
  88. Gault VA, Irwin N, Green BD, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-diabetes. Diabetes. 2005;54:2436–2446
  89. Irwin N, McClean PL, O'Harte FPM, et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist, (Pro3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia. 2007;50:1532–1540
  90. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Natural Medicines. 2002;8:738–742
  91. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure. The Journal of Clinical Investigation. 2007;117:143–152
  92. Althage MC, Ford EL, Wang S, et al. Targeted ablation of GIP-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. The Journal of Biological Chemistry. 2008;283:18365–18376
  93. Parker JC, Irwin N, Lavery KS, et al. metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biological Chemistry. 2007;388:221–226
  94. McClean PL, Gault VA, Irwin N, et al. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes, Obesity & Metabolism. 2008;10:336–342
  95. Gault VA, McClean PL, Cassidy RC, et al. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia. 2007;50:1752–1762
  96. Flatt PR. Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?. Diabetic Medicine. 2008;25:759–764
  97. McClean PL, Irwin N, Cassidy RS, et al. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances in mice by prolonged consumption of high fat diet. American Journal of Physiology. Endocrinology and Metabolism. 2007;293:E1746–E1755
  98. Yki-Jarvinen H. Insulin resistance in type 2 diabetes. In:  Pickup JC,  Williams G editor. 3rd edn.. Textbook of diabetes. 22:Oxford: Blackwell Science; 2003;p. 1–19
  99. Zhou H, Yamada Y, Tsukiyama K, et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochemical and Biophysical Research. 2005;335:937–942
  100. Irwin N, McClean PL, Patterson S, et al. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes Biological chemistry 2009; 390: 75–80.
  101. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?. Diabetes & Vascular Disease Research. 2007;4:151–153
  102. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. The American Surgeon. 2004;70:1–5
  103. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Annals of Surgery. 2004;240:236–242
  104. Muscelli E, Mingrone G, Camastra S, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. American Journal of Medicine. 2005;118:51–57
  105. Blackburn GL. Solutions in weight control: lessons from gastric surgery. American Journal of Clinical Nutrition. 2005;82(Suppl. 1):248S–252S
  106. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2479–2485
  107. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. Journal of the American Medical Association. 2004;292:1724–1737
  108. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Annals of Surgery. 2006;243:108–114
  109. Small CJ, Bloom SR. Gut hormones and the control of appetite. Trends in Endocrinology and Metabolism. 2004;15:259–263
  110. Korner J, Bessler M, Inabnet W, et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for Obesity and Related Diseases. 2007;3:597–601
  111. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  112. Merani S, Truong W, Emamaullee JA, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology. 2008;[Epub ahead of print]

PII: S1521-690X(09)00020-7

doi: 10.1016/j.beem.2009.03.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 499-512 , August 2009

Article Tools

* Image Usage & Resolution